2026年美国临床肿瘤学会（ASCO)年会将于2026年5月29日-6月2日在美国伊利诺伊州芝加哥举行。目前ASCO 2026的abstract和poster均可查看，现挑选poster中的肺癌中的部分内容进行分享，其他感兴趣的大家可以自行查看。
1. Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)─directed antibody-drug conjugate (ADC), plus pembrolizumab: Updated results from the phase 1 study (SGNB6A-001).Sigvotatug vedotin (SV，辉瑞制药)，一种在研的整合素β6（IB6）靶向抗体偶联药物（ADC），联合帕博利珠单抗：1期研究（SGNB6A-001）的更新结果。2. Dose-escalation results from a phase I study of FZ-AD004, a TROP2-directed ADC, in patients with advanced solid tumors.FZ-AD004（一种TROP2靶向ADC，复旦张江）在晚期实体瘤患者中I期研究的剂量递增结果。3. SHR-1826, a c-MET directed antibody-drug conjugate (ADC), in advanced solid tumors: Updates from a phase 1 study.SHR-1826（恒瑞医药），一种针对c-MET的抗体偶联药物（ADC），用于晚期实体瘤：一项1期研究的最新进展。4. SHR-A2102 in combination with adebrelimab as first-line treatment in patients with locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC): Results from a phase 1b/2 study.SHR-A2102（Nectin-4 ADC，恒瑞医药）联合adebrelimab（PD-L1单克隆抗体）作为局部晚期或转移性鳞状或非鳞状非小细胞肺癌（NSCLC）患者的一线治疗：一项1b/2期研究的结果。5. Necitumumab plus pembrolizumab and chemotherapy for untreated advanced squamous NSCLC: Phase I/II NEJ048A/NEXUS.Necitumumab（EGFR拮抗剂，礼来制药）联合帕博利珠单抗及化疗用于未经治疗的晚期鳞状非小细胞肺癌：I/II期NEJ048A/NEXUS研究。6. First-in-human study of DM005, an anti-EGFR/c-MET bispecific antibody-drug conjugate, in patients with advanced solid tumors.DM005（一种抗EGFR/c-MET双特异性抗体偶联药物，多玛医药）在晚期实体瘤患者中的首次人体研究。7. Comparing becotarug plus osimertinib with a real-world osimertinib therapy cohort in platinum-refractory, advanced non–small cell lung cancer with EGFR exon 20 insertion.在铂类耐药、EGFR 20外显子插入的晚期非小细胞肺癌中，比较becotarug（EGFR单克隆抗体，石药集团）联合奥希替尼与真实世界奥希替尼治疗队列的效果。8. Combination of golidocitinib (a JAK1 inhibitor) with anti–PD-1 antibody to improve tumor response and patient quality of life: Preliminary results from an ongoing JACKPOT 33 study.golidocitinib（一种JAK1抑制剂，迪哲医药）联合抗PD-1抗体改善肿瘤反应和患者生活质量：一项正在进行的JACKPOT 33研究的初步结果。9. Safety and efficacy of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer: Results from a phase 1/2 study.CS2009（一种首创的PD-1/VEGF/CTLA-4三特异性抗体，基石药业）在晚期非小细胞肺癌患者中的安全性和有效性：一项1/2期研究的结果。10. Efficacy, safety, and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to standard of care (SOC) first-line (1L) therapy: The phase 2 TeLuRide-005 trial in stage 4 NSCLC.在标准治疗（SOC）一线（1L）疗法中加入Toll样受体（TLR）7/8双激动剂EIK1001（Eikon Therapeutics）的疗效、安全性和细胞因子谱分析：4期非小细胞肺癌（NSCLC）的2期TeLuRide-005试验。11. SHR-1701 combined with fuzuloparib and chemotherapy as first-line therapy for advanced lung squamous cell carcinoma: Efficacy and safety results from a phase II study.SHR-1701（PD-L1/TGF-βRⅡ双特异性抗体融合蛋白，恒瑞医药）联合富唑帕利和化疗作为晚期肺鳞状细胞癌的一线治疗：一项II期研究的有效性和安全性结果。12. 1L olomorasib plus pembrolizumab +/- chemotherapy in KRAS G12C-mutant NSCLC patients +/- a prior cycle of SOC: Results from LOXO-RAS 20001 and SUNRAY-01.1L olomorasib（第二代KRAS G12C抑制剂，礼来制药） 联合 pembrolizumab +/- 化疗用于 KRAS G12C 突变 NSCLC 患者 +/- 既往标准治疗：LOXO-RAS 20001 和 SUNRAY-01 的结果。13. A phase II study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for non–small cell lung cancer (NSCLC).HB0025（一种PD-L1/VEGF双特异性抗体，华海药业）联合化疗作为非小细胞肺癌（NSCLC）一线治疗的II期研究。14. Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)–targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH).A2B694（A2 Biotherapeutics, Inc.）在HLA-A*02杂合性丢失（LOH）的晚期实体瘤患者中，作为一种逻辑门控间皮素（MSLN）靶向Tmod嵌合抗原受体T细胞（CAR T）疗法的初步安全性和有效性。15. Phase I study of IMM2510, a PD-L1/ VEGF bispecific antibody, in participants with advanced IO-treated SQ-NSCLC.IMM2510（一种PD-L1/VEGF双特异性抗体，宜明昂科）在接受过免疫治疗的晚期鳞状非小细胞肺癌患者中的I期研究。16. IBI363 (TAK-928) plus chemotherapy as first-line (1L) treatment for advanced non–small cell lung cancer (NSCLC).IBI363 (TAK-928，PD-1/IL-2α-bias双特异性抗体融合蛋白，信达生物) 联合化疗作为晚期非小细胞肺癌 (NSCLC) 的一线 (1L) 治疗。17. Resistance mechanisms and efficacy of first-line alectinib and sequential treatments in advanced ALK+ NSCLC: Real-world outcomes from a multicenter, observational study in Japan (ALCURE).晚期ALK+ NSCLC一线阿来替尼（罗氏制药）及后续治疗的耐药机制与疗效：日本多中心观察性研究（ALCURE）的真实世界结果。18. Afatinib versus osimertinib for non–small cell lung cancer with uncommon epidermal growth factor receptor mutations: Real-world outcomes (HOT-Next001/HOT2501).阿法替尼（德国勃林格殷格翰公司）与奥希替尼治疗罕见表皮生长因子受体突变的非小细胞肺癌：真实世界结果（HOT-Next001/HOT2501）。19. Brigatinib after lorlatinib and/or chemotherapy following first-line alectinib in ALK-rearranged NSCLC: Cohort B of the WJOG11919L/ABRAID study.在ALK重排非小细胞肺癌中，一线阿来替尼治疗后使用洛拉替尼（辉瑞制药）和/或化疗，随后使用布格替尼：WJOG11919L/ABRAID研究的B组。20. High-dose furmonertinib in EGFR-mutated advanced NSCLC with brain metastases after EGFR-TKI resistance: The iFORCE phase II trial.高剂量伏美替尼（第三代EGFR-TKI靶向药，上海艾力斯）治疗EGFR突变晚期非小细胞肺癌脑转移患者（EGFR-TKI耐药后）：iFORCE II期临床试验。21. Sotorasib vs adagrasib in the 2L+ setting: Outcomes in a large, multi-institutional, real-world database of KRAS-G12C mutated mNSCLC.索托拉西布（安进制药）与阿达格拉西布（Mirati Therapeutics（现已被BMS收购））在二线及以上治疗中的对比：基于KRAS-G12C突变转移性非小细胞肺癌的大型多中心真实世界数据库的结局分析。22. Profiling patients with MET exon 14 (METex14) skipping NSCLC with a sustained clinical benefit to tepotinib in VISION.VISION研究中对MET外显子14（MET ex14）跳跃非小细胞肺癌患者进行特征分析，以评估其对特泊替尼（一种口服MET酪氨酸激酶抑制剂，日本武田制药）的持续临床获益。23. COPERNICUS, a pragmatic phase 2b study of first-line (1L) subcutaneous (SC) amivantamab (ami) + lazertinib (laz) with supportive care in EGFR-mutated advanced NSCLC: Early safety results.COPERNICUS，一项关于一线（1L）皮下（SC）amivantamab（ami）+ lazertinib（laz，第三代EGFR-TKI，韩国柳韩洋行）联合支持治疗用于EGFR突变晚期NSCLC的实用性2b期研究：早期安全性结果。24. Safety and efficacy of APS03118, a next-generation RET inhibitor, in patients with non-small cell lung cancer (NSCLC): Results from a phase I clinical trial.下一代RET抑制剂APS03118（志健金瑞）在非小细胞肺癌（NSCLC）患者中的安全性和有效性：I期临床试验结果。25. Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis.拉罗替尼（Loxo Oncology（后被礼来收购））治疗TRK融合肺癌患者的疗效与安全性：一项更新分析。26. First-in-human dose-escalation study of the selective EGFR/HER2 exon 20 inhibitor PFL-721 in patients with locally advanced or metastatic NSCLC.选择性EGFR/HER2外显子20抑制剂PFL-721（EGFR抑制剂，Pierre Fabre Laboratories）在局部晚期或转移性非小细胞肺癌患者中的首次人体剂量递增研究。27. Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutations.silevertinib (BDTX-1535，四代EGFR TKI，Black Diamond Therapeutics, Inc.) 在既往接受过治疗的非经典和 C797S EGFR 突变非小细胞肺癌患者中 2 期研究的安全性和有效性结果。28. SOHO-01: Updated safety and efficacy of sevabertinib in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC).SOHO-01：更新的sevabertinib（HER2靶点抑制剂，拜耳医药）在晚期HER2突变非小细胞肺癌（NSCLC）患者中的安全性和有效性。29. Safety and antitumor activity of VRN110755, a brain-penetrant, selective EGFR inhibitor, in patients with EGFR-driven non–small cell lung cancer.VRN110755（一种可穿透血脑屏障的选择性EGFR抑制剂，Voronoi, Inc.）在EGFR驱动的非小细胞肺癌患者中的安全性和抗肿瘤活性。30. Efficacy and safety of deulorlatinib (TGRX-326) in patients with locally advanced or metastatic ALK+ non–small cell lung cancer: A multicenter, open-label, pivotal phase 2 trial.deulorlatinib (TGRX-326，ALK/ROS1抑制剂，深圳市塔吉瑞生物医药有限公司) 在局部晚期或转移性 ALK+ 非小细胞肺癌患者中的有效性和安全性：一项多中心、开放标签、关键性 2 期试验。31. Clinical efficacy and tolerability of the selective RET inhibitor soxataltinib (SY-5007) in advanced RET fusion–positive non–small cell lung cancer (NSCLC): Primary findings from a confirmatory phase III trial.选择性RET抑制剂soxataltinib（SY-5007，首药控股）在晚期RET融合阳性非小细胞肺癌（NSCLC）中的临床疗效与耐受性：一项确证性III期试验的主要结果。32. Results from OCEAN II: A phase II study of encorafenib + binimetinib combination in Chinese patients with BRAFV600E mutated metastatic non-small cell lung cancer.OCEAN II研究结果：一项关于中国BRAF突变转移性非小细胞肺癌患者接受encorafenib + binimetinib（BRAF+MEK）联合治疗的II期研究。33. A phase 2 multicenter, open-label, parallel cohort study to evaluate the efficacy, safety, and pharmacokinetic profile of ABN401 in patients with advanced solid tumors harboring c-MET dysregulation.一项2期多中心、开放标签、平行队列研究，旨在评估ABN401（c-MET抑制剂，Abion Inc.）在携带c-MET失调的晚期实体瘤患者中的疗效、安全性和药代动力学特征。34. A phase Ib study of osimertinib and tegavivint as first-line therapy in patients with metastatic EGFR-mutated non–small cell lung cancer (NSCLC).奥希替尼和特加维汀（TBL1拮抗剂，美国Iterion Therapeutics公司）作为转移性EGFR突变非小细胞肺癌（NSCLC）患者一线治疗的Ib期研究。35. Combination of tulmimetostat and PD-1 blockade for patients with advanced non–small cell lung cancer who progressed from first or second line of treatments.图尔米司他（EZH1/EZH2抑制剂，诺华制药）与PD-1阻断剂联合用于一线或二线治疗进展的晚期非小细胞肺癌患者。36. First-in-human phase I, open-label, multicenter study of HJ-004, a novel EGFR-PROTAC degrader, in patients with advanced EGFR-mutated non–small cell lung cancer.HJ-004（一种新型EGFR-PROTAC降解剂，和径医药科技（上海）有限公司）在晚期EGFR突变非小细胞肺癌患者中的首次人体I期、开放标签、多中心研究。37. KEYMAKER-U01J: Calderasib plus pembrolizumab with or without cetuximab as first-line treatment for advanced or metastatic nonsquamous non–small-cell lung cancer (NSCLC) with KRAS G12C mutations.KEYMAKER-U01J：卡尔德拉西布（KRAS G12C抑制剂，默沙东医药）联合帕博利珠单抗，联合或不联合西妥昔单抗，作为携带KRAS G12C突变的晚期或转移性非鳞状非小细胞肺癌（NSCLC）的一线治疗。38. An ongoing phase 1–2a study of EO1001, an oral brain-penetrant pan-ErbB inhibitor, in patients with advanced ErbB-driven solid tumors including CNS disease.一项正在进行的1-2a期研究，评估口服脑渗透性泛ErbB抑制剂EO1001（EGFR/HER2/HER4抑制剂，Edison Oncology Holding Corp.）在包括中枢神经系统疾病在内的晚期ErbB驱动型实体瘤患者中的疗效。
